Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZWI-001
- Development stage
- Preclinical
- Lead developer
- ZWI Therapeutics
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
**ZWI-001** is a preclinical-stage investigational drug developed by ZWI Therapeutics, consisting of a uricase-polycarboxybetaine conjugate designed to treat conditions associated with elevated uric acid levels, such as gout or tumor lysis syndrome. Uricase enzymatically degrades uric acid into allantoin, a more soluble metabolite, while the polycarboxybetaine conjugation likely aims to reduce immunogenicity and improve pharmacokinetics compared to native uricase therapies like pegloticase. The program has demonstrated preclinical proof-of-concept, supported by a recent Series A financing to advance development.[9]
Beyond the preview
Go deeper on ZWI-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZWI-001.